Delivery Order SPE2DB20D9127-SPE2DB25FPRQ1
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,262.76 to DMS Pharmaceutical Group Inc. on August 18, 2025, for the supply of TYSABRI 300 mg/15 ml vials. This firm fixed-price delivery order is scheduled for completion by September 9, 2025, with performance taking place at the vendor's facility in Park Ridge, Illinois. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis despite its status as a woman-owned...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,788.28 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Tysabri 300 mg/15 ml vials. This firm fixed-price delivery order, awarded on June 2, 2025, with an ultimate completion date of June 24, 2025, was issued without a set-aside designation. DMS Pharmaceutical Group is executing this order under its existing Indefinite Delivery...
- The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a $41,265.44 firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of Tysabri 300 mg/15 ml vials over a period ending on May 15, 2024. This delivery order was issued under DMS Pharmaceutical Group's existing indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999,...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Tysabri 300 mg/15 ml vials. The contract, valued at $5,262.76 with a firm fixed-price arrangement, is scheduled for completion by August 18, 2025. This delivery order was issued without a set-aside designation, allowing the vendor to compete directly in the open federal marketplace despite its small...
- On June 16, 2025, the Defense Logistics Agency (DLA), operating under the Medical Supply Chain division, awarded a delivery order valued at $21,051.08 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This firm fixed-price delivery order, with an ultimate completion date of July 9, 2025, is for the supply of TYSABRI 300 mg/15 ml vials. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Tysabri 300 mg/15 ml vials. The contract, valued at $21,051.08 with a firm fixed-price structure, was executed on September 16, 2025, with an ultimate completion date of October 7, 2025. This delivery order was issued without a set-aside designation, allowing DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on September 2, 2025, valued at $10,525.54 for the supply of TYSABRI 300 mg/15 mL vials. The contract carries an ultimate completion date of September 23, 2025, and was awarded without a set-aside designation. This delivery order represents a single pharmaceutical product acquisition executed under...
- The Defense Logistics Agency awarded a $52,627.70 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of TYSABRI 300 mg/15 ml vials. The contract, issued on June 4, 2025, with an ultimate completion date of June 26, 2025, carries no set-aside designation. This delivery order represents a near-term pharmaceutical supply requirement fulfilled through DMS Pharmaceutical Group's...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a $52,627.70 firm fixed-price delivery order from the Defense Logistics Agency on September 4, 2025, for TYSABRI 300 mg/15 ml vials. The contract, with an ultimate completion date of September 25, 2025, carries no set-aside designation and represents performance at the company's Park Ridge, Illinois location. This delivery order falls under DMS Pharmaceutical Group's...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $10,316.36 firm fixed-price contract is for the delivery of Tysabri 300 mg/15 ml vials. DMS Pharmaceutical Group holds a larger, single-award indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through December 31, 2025. This IDC allows the DLA to issue delivery...
- SPE2DB20D9127Indefinite Delivery Contract
- SPE2DB20D9127-SPE2DB25FPRQ1Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $52,627.70 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of TYSABRI 300 mg/15 mL vials. This firm fixed-price delivery order, issued on September 25, 2025, with an ultimate completion date of October 17, 2025, represents a specific procurement action under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program. The IDC, valued at $499,999,999 and valid through November 2026, authorizes DLA to issue delivery orders for a comprehensive range of pharmaceutical products supporting military healthcare facilities worldwide. This particular order carries no set-aside designation, allowing the contractor to compete on equal footing in the federal pharmaceutical supply market. DMS Pharmaceutical Group serves as a critical supplier within the federal pharmaceutical supply chain, providing prescription medications, biologics, and medical consumables to Department of Defense healthcare sites. The company's established portfolio includes delivery of specialized pharmaceutical products such as oncology treatments, vaccines, auto-injectors, and branded medications. The award of this TYSABRI delivery order reflects DMS Pharmaceutical Group's continued role in ensuring consistent pharmaceutical supply to military health facilities, with performance to be conducted at the company's Park Ridge, Illinois location.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $52.6k | 9/25/25 |